Jump to content

Surly #Stonks

Wally Fairway

By Wally Fairway
in Business and Markets

 Share

Recommended Posts

Trey3216

Trey3216 15325

Posted
Posted
16 hours ago, Wally Fairway said:

GERN write up

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gern/geron/news/with-71-ownership-of-the-shares-geron-corporation-nasdaqgern

Was this a "Kamala Harris AI report" about GERN's institutional ownership?  

 

"Geron has 71% of its shares owned institutionally, so that means institutions own a great majority of it.  So what does that mean?  Institutions own 71% of the shares!"  

 

not really a write up, but it is good that institutions are betting on it.  

  • Hook 'Em 2
Link to comment
Share on other sites
  • Replies 9.5k
  • Created
  • Last Reply

Top Posters In This Topic

Popular Days

Top Posters In This Topic

Popular Days

Popular Posts

Hank_Hill
Hank_Hill

Haven't mentioned it because didn't need naysayers because it is stupid, but I'm a med student doing this almost purely on my student loans while they're at zero interest. I've made +$20k since Decemb

Hank_Hill
Hank_Hill

The real treasure is the friends we make along the way

BradInATX
BradInATX

As long as 700% APR payday loans exist, you can fuck right off with "protecting people from themselves".

Posted Images

KYHorn

KYHorn 16877

Posted
Posted
5 minutes ago, Trey3216 said:

IBRX goes up to $4, IBRX comes back to $3.25.  

 

WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

If it helps with perspective, it was above $9 in April!

Link to comment
Share on other sites
StassneyHorn

StassneyHorn 6563

Posted
Posted
On 10/10/2024 at 2:18 PM, 52-80 said:

I sold out all my Palantir around last month at $33 because I thought it was overpriced (cost basis 16 or something)
 

Been on a straight line the last 30 days, at $43 now ☠️

Pre or post announcement to S&P 500?

Link to comment
Share on other sites
Blotto

Blotto 23460

Posted
Posted
6 hours ago, T’Boo Ted Marshall said:

It started at .93 yesterday.
How the hell does that happen?

https://finance.yahoo.com/news/bright-minds-unaware-material-changes-010900911.html

Some dude released it as a hot "buy" on a penny stock discord server, people started buying it, and due to the low float (4.5M)  it takes off, causes more people to buy it,etc.... just another pump and dump, although more successful than most. Probably be back down to $1-2 before long. 

  • Like 1
Link to comment
Share on other sites
GoneFission

GoneFission 2

Posted
Posted
11 hours ago, B00M said:

Should we sell UUUU, keep buying regardless, or wait for it to come back? 

It's a stock with a lot of volatility. They seem to have transitioned from a pure uranium play to being more rare earth's with a chunk of uranium still. I got out when they made the acquisition of the African mining company a few months ago and am not looking back. 

Link to comment
Share on other sites
Harrison Stafford

Harrison Stafford 3327

Posted
Posted
On 10/17/2024 at 7:57 AM, Hefeweizen said:

Username oddly specific!  I am watching UUUU but not in it right now.  Just wallowing in my miserable IBRX waiting room.  One of these days we’ll get some Anktiva sales preview and hopefully start moving.

Revenue from Anktiva sales for the treatment of bladder cancer should begin showing up in each of the next several quarters and the application to the EU and UK for Anktiva approval should be completed before the end of the year.  This would expand IBRX’s bladder cancer therapy to 30 countries making it available as early as mid-2025.  The NSCLC trial would be huge if it shows similar results to the quilt trial. That’s the largest cancer market in the world.

  • Hook 'Em 1
Link to comment
Share on other sites
Harrison Stafford

Harrison Stafford 3327

Posted
Posted

“EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio stock with a Buy rating and a $30 price target on Wednesday. That implies a startling 767% upside to its current share price of $3.46.

ImmunityBio is a San Diego, Calif.-based late-stage clinical biotech poised to revolutionize cancer immunotherapy, according to Kolbert.

The company’s lead product Anktiva works by activating the body’s natural immune system to eliminate tumor cells and provide long-term immune memory against cancer. It was approved by the Food and Drug Administration in April this year for adult patients with a cancer unresponsive to the most common intravesical immunotherapy (BCG), non-muscle invasive bladder cancer.

 

Anktiva’s ability to convert cold tumors into hot ones—making them more responsive to immune attack—is particularly effective as cold tumors typically evade detection, Kolbert noted. This can potentially improve outcomes in various cancers, including those traditionally treated with checkpoint inhibitors, such as melanoma, lung, ovarian, and colorectal cancers, by making them more vulnerable to an immune system attack, he added.

The small-cap company has a market value of $2.8 billion, and has yet to report a quarterly profit since its listing on Nasdaq in March 2021, which isn’t uncommon for start-up biotechs.

The stock rose 8.7% to $3.76 Thursday. At Wednesday’s close, the stock was down 31% for the year”.

^^^^^^^^^^^^^^^^^^^^^

An article in today’s Barron’s.  IBRX +.68 to $4.14.  Today’s price will be a distant memory when the stock’s at $100/share.  

  • Hook 'Em 1
Link to comment
Share on other sites
MonkeyDoughnut

MonkeyDoughnut 10184

Posted
Posted

IBRX Adding news from this morning...

  • Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors

  • First natural killer cell-based cellular therapy study conducted in the continent of Africa

  • Complete enrollment currently expected in Q1 2025

CULVER CITY, Calif., October 24, 2024--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL).

  • Hook 'Em 2
  • Like 1
Link to comment
Share on other sites
Blotto

Blotto 23460

Posted
Posted

Here's a blast from the past, one of the OG stonks on this thread. UAVS popped up on the best performing stocks today (up 50%), and I was actually surprised that they were still in business. After looking at their chart since the insanity of '21, it would appear things have been trending poorly. I still laugh at the thought that Amazon was gonna partner with these chucklefucks when Amazon had already invested in their own drone delivery business to the tune of like $30B. 

image.png.af748ca5d4ef31e697213637dd6b2dfc.png

 

This quote from the new CEO after their most recent 50:1 split a couple of days ago is fantastic:

Quote

In conclusion, through a combination of our key initiatives, growing demand, and demonstrated progress in our newest market, I believe AgEagle is on the correct path to increase long-term shareholder value. We appreciate your continued support.

Keep on stonkin', sir.

  • Haha 2
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
 Share
Go to topic listing


Football ... Basketball ... Baseball ... Other Sports ... Futbol ... 🤫995🤫 ... Gambling ... Movies & TV ... Music ... Hobbies ... Lulz ... Food & Travel ... Daily Texan ... Business and Markets ... Cloak Room ... Help ... For Sale ... Board Discussion ... Subscribe!... Donate!... Advertise... COOKIE MONSTER!

×
×
  • Create New...